New antibody therapy aims to tame lupus in early trial
NCT ID NCT07564596
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called budoprutug in 30 adults with active lupus who haven't responded well to standard treatments. The drug targets and depletes certain immune cells (B cells) to help control the disease. The main goals are to check safety and how the body processes the drug, with early signs of effectiveness also being measured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mianyang Central Hospital
ACTIVE_NOT_RECRUITINGMianyang, Sichuan, 621000, China
-
Peking University People's Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?